Organon has a market capitalisation of $1.5 billion. The US company specializes in women’s health. It spun off from Merck Sharp & Dohme in 2021.
Organon has a market capitalisation of $1.5 billion. The US company specializes in women’s health. It spun off from Merck Sharp & Dohme in 2021.